Zacks Research Has Bearish Forecast for PBH Q1 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at Zacks Research reduced their Q1 2027 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, June 16th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.25 per share for the quarter, down from their prior estimate of $1.26. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.29 EPS.

Several other equities research analysts also recently weighed in on the stock. Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, May 17th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $83.51 on Thursday. Prestige Consumer Healthcare has a fifty-two week low of $64.63 and a fifty-two week high of $90.04. The firm’s 50 day moving average price is $83.91 and its 200 day moving average price is $82.54. The company has a market cap of $4.13 billion, a P/E ratio of 19.47, a PEG ratio of 2.51 and a beta of 0.45. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same period in the prior year, the firm earned $1.02 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently bought and sold shares of PBH. Kestra Investment Management LLC acquired a new stake in Prestige Consumer Healthcare in the fourth quarter valued at $27,000. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare in the 1st quarter valued at about $38,000. CIBC Private Wealth Group LLC increased its holdings in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $40,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.